FFA
BDTX icon

Farther Finance Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Farther Finance Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$149 – 4508
2025
Q1 		$149 Hold
100
– – ﹤0.01% 4005
2024
Q4 		$214 Buy
+100
New +$287 ﹤0.01% 3645

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Farther Finance Advisors's BDTX Position: Q2 2025 in Review

Farther Finance Advisors sold out of Black Diamond Therapeutics (BDTX) in Q2 2025, closing a stake of 100 shares — an estimated $149 sold.

Farther Finance Advisors first reported a position in BDTX in Q4 2024 and held it in 2 quarters. The position peaked at $214 in Q4 2024. 94 funds tracked by Wall St. Rank hold BDTX as of Q2 2025.

  • Farther Finance Advisors reported no remaining Black Diamond Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Farther Finance Advisors sold 100 Black Diamond Therapeutics shares in Q2 2025, an estimated $149.
  • Farther Finance Advisors first reported a position in Black Diamond Therapeutics in Q4 2024 and held it in 2 quarters.
  • Farther Finance Advisors's Black Diamond Therapeutics position peaked at $214 in Q4 2024.
  • 94 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2025.

Based on Farther Finance Advisors's 13F filing for Q2 2025, filed 11 Jul 2025.